These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 33390174)

  • 1. Neuropsychiatric symptoms are early indicators of an upcoming metabolic decline in Alzheimer's disease.
    Ng KP; Pascoal TA; Mathotaarachchi S; Chan YH; Jiang L; Therriault J; Benedet AL; Shin M; Kandiah N; Greenwood CMT; Rosa-Neto P; Gauthier S;
    Transl Neurodegener; 2021 Jan; 10(1):1. PubMed ID: 33390174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.
    Ng KP; Pascoal TA; Mathotaarachchi S; Chung CO; Benedet AL; Shin M; Kang MS; Li X; Ba M; Kandiah N; Rosa-Neto P; Gauthier S;
    Neurology; 2017 May; 88(19):1814-1821. PubMed ID: 28404803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons.
    Knopman DS; Jack CR; Wiste HJ; Lundt ES; Weigand SD; Vemuri P; Lowe VJ; Kantarci K; Gunter JL; Senjem ML; Mielke MM; Roberts RO; Boeve BF; Petersen RC
    Neurobiol Aging; 2014 Sep; 35(9):2096-106. PubMed ID: 24702820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropsychiatric subsyndromes and brain metabolic network dysfunctions in early onset Alzheimer's disease.
    Ballarini T; Iaccarino L; Magnani G; Ayakta N; Miller BL; Jagust WJ; Gorno-Tempini ML; Rabinovici GD; Perani D
    Hum Brain Mapp; 2016 Dec; 37(12):4234-4247. PubMed ID: 27412866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early behavioural changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network.
    Ringman JM; Liang LJ; Zhou Y; Vangala S; Teng E; Kremen S; Wharton D; Goate A; Marcus DS; Farlow M; Ghetti B; McDade E; Masters CL; Mayeux RP; Rossor M; Salloway S; Schofield PR; Cummings JL; Buckles V; Bateman R; Morris JC;
    Brain; 2015 Apr; 138(Pt 4):1036-45. PubMed ID: 25688083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations of AT(N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer's disease and cognitively unimpaired individuals.
    Ng KP; Chiew H; Rosa-Neto P; Kandiah N; Ismail Z; Gauthier S
    Transl Neurodegener; 2021 Mar; 10(1):11. PubMed ID: 33789730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.
    Förster S; Yousefi BH; Wester HJ; Klupp E; Rominger A; Förstl H; Kurz A; Grimmer T; Drzezga A
    Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1927-36. PubMed ID: 22926714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropsychiatric symptoms and brain morphology in patients with mild cognitive impairment and Alzheimer's disease with dementia.
    Siafarikas N; Alnæs D; Monereo-Sanchez J; Lund MJ; Selbaek G; Stylianou-Korsnes M; Persson K; Barca ML; Almdahl IS; Fladby T; Aarsland D; Andreassen OA; Westlye LT
    Int Psychogeriatr; 2021 Nov; 33(11):1217-1228. PubMed ID: 34399870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suicidal ideation is common in autosomal dominant Alzheimer's disease at-risk persons.
    Ng KP; Richard-Devantoy S; Bertrand JA; Jiang L; Pascoal TA; Mathotaarachchi S; Therriault J; Yatawara C; Kandiah N; Greenwood CMT; Rosa-Neto P; Gauthier S;
    Int J Geriatr Psychiatry; 2020 Jan; 35(1):60-68. PubMed ID: 31642105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific Neuropsychiatric Symptoms Are Associated with Faster Progression in Alzheimer's Disease: Results of the Prospective Dementia Registry (PRODEM-Austria).
    Defrancesco M; Marksteiner J; Kemmler G; Dal-Bianco P; Ransmayr G; Benke T; Mosbacher J; Höller Y; Schmidt R
    J Alzheimers Dis; 2020; 73(1):125-133. PubMed ID: 31744004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDG-PET and Neuropsychiatric Symptoms among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging.
    Krell-Roesch J; Ruider H; Lowe VJ; Stokin GB; Pink A; Roberts RO; Mielke MM; Knopman DS; Christianson TJ; Machulda MM; Jack CR; Petersen RC; Geda YE
    J Alzheimers Dis; 2016 Jul; 53(4):1609-16. PubMed ID: 27447426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of brain amyloidosis with the incidence and frequency of neuropsychiatric symptoms in ADNI: a multisite observational cohort study.
    Goukasian N; Hwang KS; Romero T; Grotts J; Do TM; Groh JR; Bateman DR; Apostolova LG
    BMJ Open; 2019 Dec; 9(12):e031947. PubMed ID: 31857304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behavioral and psychological subsyndromes in Alzheimer's disease using the Neuropsychiatric Inventory.
    Canevelli M; Adali N; Voisin T; Soto ME; Bruno G; Cesari M; Vellas B
    Int J Geriatr Psychiatry; 2013 Aug; 28(8):795-803. PubMed ID: 23147419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk Factors, Neuroanatomical Correlates, and Outcome of Neuropsychiatric Symptoms in Alzheimer's Disease.
    Poulin SP; Bergeron D; Dickerson BC;
    J Alzheimers Dis; 2017; 60(2):483-493. PubMed ID: 28869463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuropsychiatric symptoms and Apolipoprotein E: Associations with eventual Alzheimer's disease development.
    Burke SL; Maramaldi P; Cadet T; Kukull W
    Arch Gerontol Geriatr; 2016; 65():231-8. PubMed ID: 27111252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.
    Laforce R; Tosun D; Ghosh P; Lehmann M; Madison CM; Weiner MW; Miller BL; Jagust WJ; Rabinovici GD
    Neuroimage Clin; 2014; 4():508-16. PubMed ID: 24818077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of BDNFVal66Met on disease markers in dominantly inherited Alzheimer's disease.
    Lim YY; Hassenstab J; Goate A; Fagan AM; Benzinger TLS; Cruchaga C; McDade E; Chhatwal J; Levin J; Farlow MR; Graff-Radford NR; Laske C; Masters CL; Salloway S; Schofield P; Morris JC; Maruff P; Bateman RJ;
    Ann Neurol; 2018 Sep; 84(3):424-435. PubMed ID: 30014553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal Changes in Serum Glucose Levels are Associated with Metabolic Changes in Alzheimer's Disease Related Brain Regions.
    Burns CM; Kaszniak AW; Chen K; Lee W; Bandy DJ; Caselli RJ; Reiman EM
    J Alzheimers Dis; 2018; 62(2):833-840. PubMed ID: 29480176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropsychiatric Symptoms as Risk Factors for Cognitive Decline in Clinically Normal Older Adults: The Cache County Study.
    Burhanullah MH; Tschanz JT; Peters ME; Leoutsakos JM; Matyi J; Lyketsos CG; Nowrangi MA; Rosenberg PB
    Am J Geriatr Psychiatry; 2020 Jan; 28(1):64-71. PubMed ID: 31186157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement.
    Ossenkoppele R; Zwan MD; Tolboom N; van Assema DM; Adriaanse SF; Kloet RW; Boellaard R; Windhorst AD; Barkhof F; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BN
    Brain; 2012 Jul; 135(Pt 7):2115-25. PubMed ID: 22556189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.